Under the terms of the purchase, GenoLogics will become part of Illumina's enterprise informatics business.
In a regulatory document, the company said the layoffs resulted from a restructuring plan to "emphasize growth initiatives."
The initiative aims to integrate clinical, genomic, environmental, and other data from patients to help determine disease mechanisms and develop precise therapies.
The researchers compared five programs used to call variants from pooled sequence data evaluating them in terms of run times, memory usage, sensitivity, and specificity.
In conjunction with its 51 percent stake in Immuneering, Teva will have the right of first refusal in projects related to CNS disorder treatments.
In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.
Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.
The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.
In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.